Clinical Trials Logo

Chronic Obstructive Pulmonary Disease clinical trials

View clinical trials related to Chronic Obstructive Pulmonary Disease.

Filter by:

NCT ID: NCT05381415 Not yet recruiting - COPD Clinical Trials

Effect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD

BREATH COPD
Start date: June 10, 2024
Phase:
Study type: Observational

During bronchodilator tests, it's common to ask patients with asthma or chronic obstructive pulmonary disease (COPD) to take bronchodilator therapy by inhaling after a maximal exhalation, when the respiratory system volume equals the residual volume. The same maneuver is required for the chronic therapy. Nevertheless, in patients with COPD the distribution of ventilation is more heterogeneous, especially when lung volumes are closer to residual volume . It is therefore predictable that the distribution of air volume containing bronchodilator that has been inhaled at residual volume is more heterogeneous than at higher volumes, such as at functional residual capacity. Accordingly, the bronchodilator can be preferentially distributed in more open airways than in less patent ones, with a heterogeneous distribution of the medication. Therefore, the overall bronchodilation should be greater when the drug inhalation is performed at functional residual capacity than at residual volume. It is common knowledge that the effectiveness of bronchodilator therapy with pMDI in subjects with COPD is greatly affected by the inhalation technique, which can be difficult to perform for many patients. Therefore, in addition to the possibility that inhalation of bronchilation therapy at residual volume could lower the drug effectiveness, this maneuver complicates the sequence of actions required to the patient, enhancing the risk of errors and decreasing the aderence to treatment. The aim of this study is to investigate whether the inhalation of a bronchodilator at different lung volumes can affect its effectiveness in terms of respiratory function, in patients with COPD. Assuming that the bronchodilator effectiveness is equal or greater when inhaled at functional residual capacity rather than at residual volume, the inhalation maneuver can be simplified for patients with COPD.

NCT ID: NCT05357274 Not yet recruiting - Asthma Clinical Trials

A System to Classify Treatable Traits in Primary Care

SMART
Start date: May 16, 2022
Phase:
Study type: Observational

This study proposes an approach to address an urgent unmet need in clinical practice, namely a pragmatic method of establishing what is the cause of a patient's complaint and the next steps to address this problem. In this study, the investigators will compare the proposed classification with current best practice of self-report, spirometry and FeNO. The investigators will compare the two approaches with a gold standard of deep characterisation by 3 separate diagnostic tests. The investigators hypothesize that patients with symptoms of respiratory disease fall into one of four working groups based on accurate knowledge of three parameters, airflow, treatment use and the patient's symptoms.

NCT ID: NCT05335304 Not yet recruiting - COPD Clinical Trials

The Effects of Different Physiotherapy Approaches in Stable COPD Patients.

Start date: April 18, 2022
Phase: N/A
Study type: Interventional

In our study, the effects of Kinesio Taping (KT), Rigid Taping (RT), Thoracic Mobilization (TM) and Core Stabilization (KS) approaches on respiratory muscle morphology, respiratory muscle strength, exercise capacity and quality of life will be examined in stable COPD patients. Study is designed as prospective, single-blinded, randomized-controlled study.

NCT ID: NCT05320939 Not yet recruiting - COPD Clinical Trials

Immunological Basis for Mepolizumab Activity in COPD

Start date: April 2023
Phase: Phase 2
Study type: Interventional

The current literature suggests that the mode of action of mepolizumab is to bind with Interleukin (IL)-5 and block the interaction of IL-5 with the IL-5Ra receptor on eosinophils. This removal of IL-5 may not explain all of the effects of mepolizumab. The investigators propose a set of studies to systematically examine the spectrum of effects of this drug on the immune system.

NCT ID: NCT05292053 Not yet recruiting - Copd Clinical Trials

Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

Sundial-COPD
Start date: April 1, 2022
Phase: Phase 4
Study type: Interventional

This is a single-center, prospective, open-label study evaluating outcomes of TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder) on PRN nebulized short-acting beta agonist (SABA) treatment in hospitalized subjects with COPD with or without asthma. Approximately 80 adult subjects with COPD with or without asthma will take part in this study at this location. Subjects will be given TRELEGY ELLIPTA, placed on a consistent short-term systemic corticosteroid therapy, and followed until 30 days post hospital discharge. This study will not include patients with rapidly deteriorating or potentially life-threatening episodes of COPD or asthma.

NCT ID: NCT05273359 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)

Start date: April 2023
Phase: Phase 2
Study type: Interventional

The current literature suggests that the mode of action of benralizumab is to deplete eosinophils through a mechanism of antibody-dependent cell-mediated cytotoxicity. This direct cellular cytotoxicity may not explain all of the benralizumab effects. The investigators propose a set of studies to systematically examine the spectrum of effects of this drug on the immune system.

NCT ID: NCT05271474 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

COPD Remote Patient Monitoring Through Connected Devices

Start date: June 2022
Phase: N/A
Study type: Interventional

This study is a device study that will use a double-arm. It will integrate the ANNE ONE platform which continuously tracks enrolled COPD patients' vital signs and symptoms over the course of the study and digitally shares that data with providers for clinical interpretation, potential intervention and treatment decision making and will help evaluate the impact on participating patient's COPD Assessment Test (CAT) scores. Subjects will be recruited from Emory clinics and identified via a data pull based on clinical relevant codes. Letters will be sent out to eligible candidates and interested participants will contact the research team. The research team will consent them over the phone and mail the device to them; participants will be compensated.

NCT ID: NCT05264441 Not yet recruiting - Asthma Clinical Trials

Choice of Inhalation Device

Choice Device
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

In this study, asthma and COPD patients will be invited to participate after the consultation with their pulmonologist. The intervention consists of three steps. The first step is to perform a deep inspiration. The second step is to demonstrate the correct use of a pMDI. The third step is to perform a strong inspiration into the In-Check Dial device over 5 different resistances.

NCT ID: NCT05213507 Not yet recruiting - COPD Clinical Trials

Inhaled Amikacin in Preventing AECOPD

Start date: March 2022
Phase: Phase 3
Study type: Interventional

The underlying bacterial colonization in lower respiratory tract (LRT) of COPD patients may be related to acute exacerbation of COPD (AECOPD) and disease progression. However, there is a lack of strong evidence on the effect of LRT bacterial decolonization on COPD. This study was designed to confirm the prophylactic effect of decolonization of LRT bacteria on AECOPD and establish a novel prophylactic therapy for sable COPD.

NCT ID: NCT05211674 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Analysis of Postural Control of COPD Patients (ATTRACTION)

ATTRACTION
Start date: February 2022
Phase:
Study type: Observational

Chronic Obstructive Pulmonary Disease (COPD) is a common chronic respiratory disease, causing disabling respiratory symptoms and impairing patients' quality of life. Currently one of the leading causes of death worldwide, COPD is a major socio-economic concern. It is also accompanied by extremely frequent extra-respiratory manifestations (or co-morbidities). Among these secondary manifestations, the equilibrium of these patients is subject to modifications: thus, numerous studies have shown that the equilibrium of COPD patients was altered compared to healthy age-matched subjects. This alteration is associated with a greater functional limitation and a higher risk of falling. Although this impairment has been demonstrated clinically, the balance of these patients has never been analysed using quantified movement analysis tools during tasks similar to those performed in daily life. Moreover, the underlying mechanisms remain unknown and the possible associations with several clinical factors of interest (pain, dyspnea, muscle function...) have not yet been assessed. The hypotheses of this project are that (1) the postural control of COPD patients is altered compared to healthy subjects during tasks of daily living and these changes can be characterised. (2) Several clinical factors are associated with these changes.